Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Neuro-Oncology

Volumn 14, Issue 2, 2012, Pages 145-159

  Ostertag, Derek ^a   Amundson, Karin K ^a   Espinoza, Fernando Lopez ^a   Martin, Bryan ^a   Buckley, Taylor ^a   Da Silva, Ana Paula Galvão ^a   Lin, Amy H ^a   Valenta, David T ^a   Perez, Omar D ^a   Ibañez, Carlos E ^a   Chen, Ching I ^a   Pettersson, Pär L ^a   Burnett, Ryan ^a   Daublebsky, Veronika ^b   Hlavaty, Juraj ^b   Gunzburg, Walter ^b   Kasahara, Noriyuki ^c   Gruber, Harry E ^a   Jolly, Douglas J ^a   Robbins, Joan M ^a  

^a Tocagen   (United States)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 fluorocyosine; brain cancer; cytosine deaminase; gene therapy; glioblastoma multiforme

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; HYDROLASE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; IMMUNOCOMPETENCE; LONG TERM SURVIVAL; LYMPHOID TISSUE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; VIRUS GENOME;

ANIMALS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; GLIOMA; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84857569415     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor199     Document Type: Article

References (48)

1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651-659. (Pubitemid 46431984)
2. Rainov NG, Heidecke V. Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma. [published online ahed of print June 27, 2011]. Anticancer Agents Med Chem.
3. Stanford MM, Bell JC, Vaha-Koskela MJ. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev. Apr-Jun 2010; 21(2-3):177-183.
4. Dalba C, Klatzmann D, Logg CR, Kasahara N. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther. 2005;5(6):655-667. (Pubitemid 43009509)
5. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 2001;61(14):5447-5452. (Pubitemid 32694925)
6. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998;95(3):1178-1183. (Pubitemid 28124932)
7. el-Tahtawy A, Wolf W. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. Cancer Res. 1991;51(21): 5806-5812.
8. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91(17):8302-8306.
9. Kuriyama S, Masui K, Sakamoto T, et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 1998;18(5A):3399-3406. (Pubitemid 28546466)
10. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res. 2000;60(23):6649-6655.
11. Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves longterm survival benefit in experimental glioma. Mol Ther. 2005;12(5):842-851. (Pubitemid 41614479)
12. Klein E, Klein G. Immunological tolerance of neonatally infected mice to the Moloney leukaemia virus. Nature. 1966;209(5019):163-165.
13. Stephenson JR, Peters RL, Hino S, et al. Natural immunity in mice to structural polypeptides of endogenous type C RNA viruses. J Virol. 1976;19(3):890-898.
14. Cornetta K, Moen RC, Culver K, et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. Spring 1990;1(1):15-30. (Pubitemid 120034738)
15. Ebeling SB, Simonetti ER, Borst HP, et al. Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious. Gene Ther. 2003;10(21):1800-1806. (Pubitemid 37185137)
16. Takeda E, Tsuji-Kawahara S, Sakamoto M, et al. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol. 2008;82(22):10998-11008.
17. Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J Virol. 2001;75(15):6989-6998. (Pubitemid 32641586)
18. Korkegian A, Black ME, Baker D, Stoddard BL. Computational thermostabilization of an enzyme. Science. 2005;308(5723):857-860. (Pubitemid 40629266)
19. Trehin R, Figueiredo JL, Pittet MJ, Weissleder R, Josephson L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia. 2006;8(4):302-311.
20. Hiraoka K, Kimura T, Logg CR, et al. Therapeutic efficacy of replicationcompetent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res. 2007;67(11):5345- 5353. (Pubitemid 46997274)
21. Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther. 2002;9(4):356-364. (Pubitemid 34289454)
22. Smilowitz HM, Weissenberger J, Weis J, Brown JD, O'Neill RJ, Laissue JA. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma. J Neurosurg. 2007; 106(4):652-659. (Pubitemid 46536463)
23. Pohl U, Wick W, Weissenberger J, et al. Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. Int J Oncol. 1999;15(4):829-834.
24. Eldadah AH, Nathanson N, Sarsitis R. Pathogenesis of West Nile Virus encephalitis in mice and rats. 1. Influence of age and species on mortality and infection. Am J Epidemiol. 1967;86(3):765-775.
25. Rodrigues T, Carvalho A, Carmo M, Carrondo MJ, Alves PM, Cruz PE. Scaleable purification process for gene therapy retroviral vectors. J Gene Med. 2007;9(4):233-243. (Pubitemid 46746314)
26. McCormack JE, Edwards W, Sensintaffer J, et al. Factors affecting longterm expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther. 2001;3(4):516-525. (Pubitemid 32519561)
27. Hlavaty J, Jandl G, Liszt M, et al. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol. 2011;102(1):59-69.
28. Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009;20(10):1119-1132.
29. Solly SK, Trajcevski S, Frisen C, et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 2003;10(1):30-39. (Pubitemid 36222074)
30. Stegman LD, Rehemtulla A, Beattie B, et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1999;96(17):9821-9826. (Pubitemid 29398816)
31. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62(3):773-780. (Pubitemid 34126953)
32. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol. 1995;154(10):5302-5312.
33. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994;54(6):1503-1506. (Pubitemid 24106413)
34. Diasio RB, Bennett JE, Myers CE. Mode of action of 5-fluorocytosine. Biochem Pharmacol. 1978;27(5):703-707. (Pubitemid 8313181)
35. Lv SQ, Zhang KB, Zhang EE, et al. Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit. 2009;15(1):BR13-20.
36. Menei P, Capelle L, Guyotat J, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery. 2005;56(2):242-248. discussion 242-248.
37. Duerner LJ, Schwantes A, Schneider IC, Cichutek K, Buchholz CJ. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue. Gene Ther. 2008;15(22):1500-1510.
38. Low A, Okeoma CM, Lovsin N, et al. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology. 2009;385(2):455-463.
39. Santiago ML, Benitez RL, Montano M, Hasenkrug KJ, Greene WC. Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol. 2010;185(2):1114-1123.
40. Rulli SJ, Jr., Mirro J, Hill SA, et al. Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol. 2008;82(13):6566-6575. (Pubitemid 351875133)
41. Miura K, Suzuki K, Imura N. Effects of methylmercury on mitotic mouse glioma cells. Environ Res. 1978;17(3):453-471. (Pubitemid 9090165)
42. Morrone FB, Oliveira DL, Gamermann P, et al. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer. 2006;6:226.
43. Walter MA, Hildebrandt IJ, Hacke K, et al. Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/-mice. J Nucl Med. 2010;51(8):1285-1292.
44. Mizoguchi M, Inamura T, Shono T, et al. A comparative study of apoptosis and proliferation in germinoma and glioblastoma. Neuro Oncol. 2000;2(2):96-102.
45. Critchley-Thorne RJ, Simons DL, Yan N, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA. 2009;106(22):9010-9015.
46. Stojdl DF, Lichty BD, ten Oever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263-275. (Pubitemid 37329791)
47. Kaushik DK, Gupta M, Basu A. Microglial response to viral challenges: every silver lining comes with a cloud. Front Biosci. 2011;17:2187-2205.
48. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci. 2002;3(3):216-227. (Pubitemid 135706591)